Table 1.
Comparison in demographic parameters, comorbidities and treatments between the study group and the control group.
| Variables | Control (N = 66) | ACEI/ARB (N = 110) | P-value |
|---|---|---|---|
| Demographics N (%) N (%) | |||
| Male | 42 (64) | 86 (78) | 0.001 |
| Female | 24 (36) | 24 (22) | – |
| Age (years) (mean ± SD) | 69.9 ± 12.7 | 68.5 ± 11.9 | 0.378 |
| Weight (kg) (mean ± SD) | 82.4 ± 18.8 | 88.6 ± 17.4 | 0.344 |
| Day of symptoms on admission (mean ± SD) | 7.27 ± 3.64 | 7.42 ± 3.45 | 0.61 |
| Comorbidities | |||
| Heart Failure | 6 (9) | 16 (15) | 0.352 |
| Pre-Heart Failurea | 60 (91) | 94 (85) | – |
| Pulmonary disease | 10 (15) | 17 (16) | 1 |
| No Pulmonary disease | 56 (85) | 93 (84) | – |
| COVID-19 treatment | |||
| Steroids | 63 (96) | 95 (86) | 0.112 |
| Remdesivir | 38 (58) | 56 (51) | 0.649 |
| Tocilizumab | 25 (38) | 38 (35) | 0.767 |
| Ivermectin | 38 (58) | 61 (56) | 0.922 |
| Convalescent Plasma | 19 (29) | 34 (31) | 0.916 |
| Bacterial co-infection treatment | |||
| Antibiotics | 43 (65) | 67 (61) | 0.842 |
a
Pre-Heart Failure” designates patients who are pre-disposed to developed heart failure and include patients who had coronary artery disease, hypertension, and arrhythmias (such as atrial fibrillation and atrial flutter).